Business
Australis Appoints Dr. Jason Dyck as Chief Science Officer
Australis Appoints Dr. Jason Dyck as Chief Science Officer.
About this update from Australis Capital Inc.
[{"type":"text","content":"\n\n\n\nAustralis Appoints Dr. Jason Dyck as Chief Science Officer\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nAustralis Appoints Dr. Jason Dyck as Chief Science Officer\nPR Newswire\nLAS VEGAS, April 12, 2021\n\n\n\nLAS VEGAS, April 12, 2021 /PRNewswire/ - Australis Capital Inc. (CSE: AUSA) (OTC: AUSAF) (\"AUSA\" or the \"Company\") today announced it has appointed Dr. Jason Dyck as its new Chief Science Officer, and Chairman of its Scientific Advisory Board. (SAB). \n\n \n \n \n \n \n \n\n \nThe appointment is in line with the Company's strategy to leverage the roots of its management team in medical cannabis, and develop offerings and partnerships that are aimed at the medical and wellness markets. Dr. Dyck has a wealth of experience in leading cannabis related medical research, as well as has deep connections and a high standing throughout the industry. Previously, Dr. Dyck led the research and science team at Aurora Cannabis in its formative years, playing a significant role in helping it become the medical cannabis industry leader that it is today. \nIn addition, a component of Dr. Dyck's research at the University of Alberta involves the study of medical cannabis users. Dr. Dyck has established the world's largest known medical cannabis database of over 160,000 patients that links these patients to comprehensive provincial administrative health data. This type of database is being used by Dr. Dyck and his colleagues at the University of Alberta to determine how medical cannabis use influences use of other medications, health insurance claims, acute and ambulatory care episodes, accident claims, and other key health outcomes.\nIn this newly created position, Dr. Dyck will be responsible for leading the Company's scientific efforts in relation to medical and wellness applications for cannabis, both THC and CBD, as well as play an important role in the identification and vetting of partnership opportunities with medical and science-based innovators. The SAB mandate will include, but is not limited to, providing advice, analysis and direction related to the scient...